US-based Celgene has reported positive results in a Phase IV trial (Unveil) that evaluates its oral, phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in patients with moderate plaque psoriasis with a body surface area (BSA) of 5% to 10%.

The trial includes 221 patients and has evaluated the clinical efficacy and safety of oral Otezla 30mg twice-daily in comparison with placebo at week 16 of the trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The patients involved in the trial were also defined as a static Physician's Global Assessment (sPGA) of 3, who were naïve to systemic and biologic therapy.

At the study baseline, more than 80% of patients enrolled in the trial had previously received topical therapy.

"Patients with moderate plaque psoriasis are often inadequately treated, and there remains an unmet medical need for safe and effective treatment options in this population."

The primary endpoint of the randomised, controlled study involves the mean percentage change from baseline in the product of PGA and BSA (PGA×BSA) at week 16 of the trial.

See Also:

UConn Health department of dermatology professor and chair Dr Bruce Strober said: “Patients with moderate plaque psoriasis are often inadequately treated, and there remains an unmet medical need for safe and effective treatment options in this population.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“While most trials focus on moderate-to-severe plaque psoriasis, this is the first randomised clinical trial of patients with moderate plaque psoriasis, and the results provide encouraging data for patients.”

According to Celgene, patients who received Otezla during week 16 of the Unveil trial had a significantly greater improvement in mean percentage change from baseline in PGA×BSA, compared with those who received placebo.

The study has also found that around 5% of the patients taking Otezla have been reported with adverse events.